Biohaven Ltd. - BHVN STOCK NEWS

Biohaven Pharmaceutical announced a worldwide licensing agreement with Bristol Myers Squibb for the development of taldefgrobep alfa, a Phase 3-ready anti-myostatin adnectin targeted at treating Spinal Muscular Atrophy (SMA). This is Biohaven's third license from Bristol Myers Squibb, with the trial expected to commence in 2022. Taldefgrobep aims to enhance muscle mass and strength in patients with neuromuscular diseases, representing a potential breakthrough in treatment strategies. The agreement includes milestone payments and sales-based royalties for Bristol Myers Squibb.

Biohaven Pharmaceutical (NYSE: BHVN) has initiated a Phase 2/3 clinical trial to evaluate the safety and efficacy of Nurtec® ODT (rimegepant) 75 mg in treating chronic rhinosinusitis (CRS), impacting 5-12% of the population. The trial aims to enroll 200 patients across 25 U.S. sites and will assess changes in facial pain and safety measures. Nurtec ODT is already FDA-approved for migraine treatment. The trial represents a potential new therapeutic option for patients suffering from this condition, addressing a significant unmet medical need in CRS management.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) will host its fourth quarter and year-end 2021 earnings call on February 25, 2022, at 8:30 a.m. ET. The call will provide financial results for the quarter ending December 31, 2021, alongside recent accomplishments and upcoming milestones. Biohaven is focusing on innovative therapies for neurological and neuropsychiatric diseases, including FDA-approved NURTEC ODT for migraine treatment and a wide pipeline targeting various conditions. For participation, call 877-407-9120 (domestic) or 412-902-1009 (international).

Biohaven Pharmaceutical and Pfizer announced successful Phase 3 trial results for rimegepant, aimed at treating migraines in 1,431 adults across the Asia-Pacific region. This trial, led by BioShin Limited, confirmed that a single 75 mg dose significantly alleviated migraine symptoms within two hours (p<0.0001) and showed sustained effectiveness for up to 48 hours. Following this success, rimegepant, currently marketed as Nurtec ODT in the U.S., has regulatory applications pending in Europe. The partnership aims to expand the drug's availability, particularly in regions where migraine remains prevalent.

Biohaven Pharmaceuticals partners with Hardware LDN at New York Fashion Week to raise awareness about migraines, affecting nearly 40 million Americans. Designer Jessica Horwell showcases a new collection featuring a classic bomber jacket promoting the word "Fearless," while four models living with migraine walk the runway. Biohaven highlights its migraine treatment, Nurtec ODT, effective in managing symptoms. The collaboration aims to empower women to advocate for better treatment options and supports public awareness regarding the impact of migraines.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) published findings in Cephalalgia Reports indicating that the long-term treatment of migraines with rimegepant 75 mg significantly reduced migraine frequency. The study involved 1,044 patients undergoing a 52-week Open Label Safety Study (BHV3000-201). Results showed a greater reduction in monthly migraine days (MMD) as patients continued with treatment, particularly in those with lower baseline MMD. The acute treatment, first FDA-approved in February 2020, highlights rimegepant's potential both for immediate relief and long-term therapeutic benefits.

Biohaven Pharmaceuticals (NYSE:BHVN) has renewed its partnership with Rick Ware Racing for the 2022 NASCAR Cup Series and NTT INDYCAR Series, following a successful inaugural season. Nurtec® ODT (rimegepant), the only FDA-approved medication that treats and prevents migraine attacks, will be featured prominently. CEO Vlad Coric emphasized the partnership's goal to raise awareness about migraines, which affect nearly 40 million Americans. The collaboration also includes military outreach, having supported service members through various visits and initiatives.

Global Coalition for Adaptive Research announced the GBM AGILE trial has screened over 1000 patients, achieving enrollment rates 3 to 4 times higher than traditional studies. Biohaven’s troriluzole and Vigeo’s VT1021 will join the trial, assessing multiple therapies for glioblastoma. The trial's expansion includes sites in Europe and China, with IND approval received for Kazia’s paxalisib. The adaptive design aims for quicker identification of effective treatments and supports rapid drug development.

Biohaven Therapeutics, a subsidiary of Biohaven Pharmaceutical (NYSE: BHVN), has announced an exclusive global licensing agreement with KU Leuven for the development of TRPM3 antagonists aimed at chronic pain disorders. The lead candidate, BHV-2100, has shown promise in preclinical models for pain management without the adverse effects of current therapies. This collaboration enhances Biohaven's pipeline, complementing their existing migraine treatments. KU Leuven will receive upfront payments and royalties, signaling a strong investment in pain management therapies.